Delivery Order SPE2DR25D9239-SPE2DR26FFBZ9
- Not listed
- The Defense Logistics Agency awarded a $46,509.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. DMS Pharmaceutical Group was selected as...
- The Defense Logistics Agency awarded a $58,869.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on January 12, 2026, with an ultimate completion date of February 3, 2026, and carries no set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical Group's Indefinite Delivery...
- The Defense Logistics Agency issued a delivery order valued at approximately $29.4K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, awarded on January 22, 2026, represents performance through February 12, 2026, and carries no set-aside designation, indicating the awardee competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- The Defense Logistics Agency awarded a delivery order valued at $49,058.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on January 22, 2026, with an ultimate completion date of February 12, 2026, was issued without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal...
- The Defense Logistics Agency awarded a delivery order valued at $27,905.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement....
- The Defense Logistics Agency awarded a $41,858.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award...
- The Defense Logistics Agency awarded a $41,441.33 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency (DLA) awarded a $139,529.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (420 mg/14 mL vials). The delivery order, issued on November 20, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $9,301.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 17, 2025, with an ultimate completion date of December 9, 2025, was awarded without set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal...
- The Defense Logistics Agency awarded a delivery order valued at $4,905.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 16, 2026, with an ultimate completion date of February 9, 2026, operates under a firm fixed-price arrangement with no set-aside designation. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery...
- SPE2DR25D9239Indefinite Delivery Contract
- SPE2DR25D9239-SPE2DR26FFBZ9Delivery Order
The Defense Logistics Agency awarded a $29,434.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 30, 2026, with an ultimate completion date of February 23, 2026, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will deliver this oncology pharmaceutical product to support Department of Defense medical supply requirements. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to military healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical supplier within the federal military medical pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.4k | 1/29/26 |